NO20033341L - Metoder for administrering av epothilone-analoger for behandling av kreft - Google Patents

Metoder for administrering av epothilone-analoger for behandling av kreft

Info

Publication number
NO20033341L
NO20033341L NO20033341A NO20033341A NO20033341L NO 20033341 L NO20033341 L NO 20033341L NO 20033341 A NO20033341 A NO 20033341A NO 20033341 A NO20033341 A NO 20033341A NO 20033341 L NO20033341 L NO 20033341L
Authority
NO
Norway
Prior art keywords
glass
analog
epothilone
mixture
cancer
Prior art date
Application number
NO20033341A
Other languages
English (en)
Other versions
NO20033341D0 (no
NO335119B1 (no
Inventor
Rebanta Bandyopadhyay
Timothy M Malloy
Andrea Panaggio
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20033341D0 publication Critical patent/NO20033341D0/no
Publication of NO20033341L publication Critical patent/NO20033341L/no
Publication of NO335119B1 publication Critical patent/NO335119B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en fremgangsmåte for formulering av visse epothilone-analoger for parenteral administrering, hvor analogen løses i en blanding av minst 50 vol% tert-butanol i vann, blandingen lyofiliseres, det resulterende lyofiliserte produkt pakkes i et glass med en tilstrekkelig mengde løsningsmiddel som omfatter vannfri etanol og et egnet ikke-ionisk overflateaktivt middel i et andre glass. Alle trinn foretas under beskyttelse mot lys. Ved bruk tilsettes innholdet av det andre glass til det lyofiliserte produkt og blandes for å rekonstituere epothilone-analogen, hvorpå den resulterende løsning fortynnes med et passende fortynningsmiddel for å frembringe en løsning for intravenøs injeksjon som inneholder epothilone-analogen i en konsentrasjon på fra ca. 0,1 mg/mL til ca. 0,9 mg/mL. Et foretrukket overflateaktivt middel er polyetoksylert ricinusolje og et foretrukket fortynningsmiddel er laktatholdig Ringers injeksjon.
NO20033341A 2001-01-25 2003-07-24 Fremgangsmåte for formulering av en epothilone-analog for parenteral administrering, farmasøytisk blanding omfattende slike samt denne forbindelsen for behandling av kreft NO335119B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000601P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (3)

Publication Number Publication Date
NO20033341D0 NO20033341D0 (no) 2003-07-24
NO20033341L true NO20033341L (no) 2003-09-04
NO335119B1 NO335119B1 (no) 2014-09-22

Family

ID=26950348

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033341A NO335119B1 (no) 2001-01-25 2003-07-24 Fremgangsmåte for formulering av en epothilone-analog for parenteral administrering, farmasøytisk blanding omfattende slike samt denne forbindelsen for behandling av kreft

Country Status (10)

Country Link
JP (1) JP4633331B2 (no)
AU (1) AU2002245296B2 (no)
CA (1) CA2434526C (no)
HR (1) HRP20030677B1 (no)
IL (1) IL156578A0 (no)
MX (1) MXPA03006412A (no)
NO (1) NO335119B1 (no)
PL (1) PL207720B1 (no)
RU (1) RU2292202C2 (no)
WO (1) WO2002058700A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
AU2008200555C1 (en) * 2003-03-14 2011-12-15 Novartis Ag Treatment of proliferative diseases with epothilone derivatives and radiation
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP3002009B1 (en) * 2007-06-01 2021-07-07 Wyeth LLC Treatment of imatinib resistant chronic myelogenous leukemia having the mutaton 1457t>c in the bcrabl gene using the compound bosutinib
WO2009089138A1 (en) * 2008-01-04 2009-07-16 Bristol-Myers Squibb Company Oral administration of ixabepilone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
WO1999004330A1 (en) * 1997-07-18 1999-01-28 Hewlett-Packard Company Format for passing information between devices
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
CN100396276C (zh) * 1998-02-05 2008-06-25 诺瓦提斯公司 依普西龙组合物
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
CN1209360C (zh) * 1999-02-18 2005-07-06 舍林股份公司 16－卤－依泊昔酮衍生物、其制备方法及其医药用途
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon

Also Published As

Publication number Publication date
HRP20030677A2 (en) 2004-08-31
HRP20030677B1 (en) 2011-10-31
WO2002058700A1 (en) 2002-08-01
AU2002245296B2 (en) 2006-12-21
CA2434526C (en) 2011-11-01
RU2292202C2 (ru) 2007-01-27
PL373727A1 (en) 2005-09-05
NO20033341D0 (no) 2003-07-24
RU2003126170A (ru) 2005-02-27
MXPA03006412A (es) 2003-10-15
IL156578A0 (en) 2004-01-04
PL207720B1 (pl) 2011-01-31
JP4633331B2 (ja) 2011-02-16
JP2005503323A (ja) 2005-02-03
CA2434526A1 (en) 2002-08-01
NO335119B1 (no) 2014-09-22

Similar Documents

Publication Publication Date Title
YU58203A (sh) Postupci primene epotilonskih analoga za lečenje kancera
BG108019A (en) Parenteral formulation containing epothilone analogs
RU2180901C2 (ru) N-замещенные 2-цианопирролидины
FR2547727A1 (fr) Compositions pharmaceutiques
RU2006147247A (ru) Фармацевтические композиции
EP0676411A2 (fr) Peptides et pseudopeptides dérivés de tachykinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
KR910004657A (ko) 레닌 억제제, 그의 제조 방법 및 그의 의약품으로서의 용도
FR2602142A1 (fr) Utilisation en therapeutique des antagonistes des recepteurs serotoninergiques 5ht3
NO20033341L (no) Metoder for administrering av epothilone-analoger for behandling av kreft
IL155333A0 (en) Sulfanilide derivatives for use in medicine, certain such new derivatives and their preparation
JPS60188317A (ja) 抗健忘症剤
CN109562186A (zh) 与炎症的专门促消退介质的盐有关的组合物和方法
EP0556482A2 (en) Propyl endopeptidase inhibitor
CN104884455B (zh) 丙型肝炎病毒抑制剂
NO153916B (no) Fremgangsmaate for fremstilling av en stabil, injiserbar opploesning av et oksytetracyklin-chelat.
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
JP3398255B2 (ja) 新規ペプチド及びそれを有効成分とする骨疾患治療薬
KR0124028B1 (ko) 후천성 면역 결핍증의 예방 및 치료제
CH653017A5 (fr) Derives s-acyles d'acides mercaptoacylamines ayant une activite inhibitrice de l'enzyme de conversion de l'angiotensine.
FR2729668A1 (fr) Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE2823834C2 (de) Farnesylcarbonsäure-α-bisabololester, Verfahren zu dessen Herstellung und diesen enthaltendes Mittel
JP2808294B2 (ja) ４―（１―イミダゾリルメチル）ケイ皮酸を有効成分として含有する薬剤
FR2537435A1 (fr) Nouvelle association medicamenteuse a base d'un alcaloide hydrogene de l'ergot de seigle et d'heparine
JPH02304024A (ja) エイズウィルス増殖抑制剤
US3895114A (en) Cyclic hydroxamic acids as antihypertensive agents

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: R-PHARM US OPERATING, US

MM1K Lapsed by not paying the annual fees